RIGL
Rigel Pharmaceuticals, Inc. NASDAQ Listed Nov 29, 2000$32.91
-1.38%
vs $33.37
Mkt Cap $620.0M
52w Low $18.42
44.5% of range
52w High $50.96
50d MA $30.19
200d MA $34.06
P/E (TTM)
1.7x
EV/EBITDA
3.8x
P/B
1.5x
Debt/Equity
0.1x
ROE
93.8%
P/FCF
8.2x
RSI (14)
66.70
ATR (14)
$1.41
Beta
1.27
50d MA
$30.19
200d MA
$34.06
Avg Volume
405.3K
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
1180 Veterans Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.80 | 0.47 | -40.9% | 28.09 | +2.2% | -5.1% | -1.6% | -0.8% | +0.6% | +12.1% | — |
| Mar 3, 2026 | AMC | 1.33 | 1.14 | -14.3% | 33.02 | -8.3% | -10.3% | -0.4% | -2.2% | -2.8% | +1.3% | — |
| Nov 4, 2025 | AMC | 0.93 | 1.46 | +57.0% | 28.38 | +22.9% | +33.4% | -4.6% | -2.6% | -1.8% | +9.8% | — |
| Aug 5, 2025 | AMC | 1.97 | 3.28 | +66.5% | 24.24 | +12.1% | +23.0% | +2.1% | +4.1% | +5.6% | +3.2% | — |
| May 6, 2025 | AMC | 0.14 | 0.63 | +350.0% | 18.26 | +23.5% | +1.2% | +2.3% | -0.7% | -0.9% | -1.7% | — |
| Mar 4, 2025 | AMC | 0.30 | 0.80 | +166.7% | 22.08 | -8.7% | -8.1% | -2.9% | +4.2% | -4.8% | -0.2% | — |
| Nov 7, 2024 | AMC | 0.06 | 0.70 | +1066.7% | 15.44 | +7.8% | +42.9% | +13.0% | +9.1% | +0.7% | +0.2% | — |
| Aug 6, 2024 | AMC | -0.37 | -0.06 | +83.8% | 9.33 | +12.5% | +5.8% | +5.7% | -2.1% | +10.2% | +12.6% | — |
| May 7, 2024 | AMC | -0.30 | -0.50 | -66.7% | 11.90 | -6.7% | -16.6% | +2.8% | -3.5% | -0.2% | -3.5% | — |
| Mar 5, 2024 | AMC | 0.02 | 0.04 | +99.9% | 14.80 | +4.1% | +5.4% | -1.9% | +2.6% | -3.8% | -1.3% | — |
| Nov 7, 2023 | AMC | -0.70 | -0.30 | +57.1% | 8.71 | +3.3% | +2.2% | -8.2% | +0.1% | -2.1% | +6.1% | — |
| Aug 1, 2023 | AMC | -0.80 | -0.40 | +50.0% | 13.30 | +1.5% | -3.0% | -2.3% | -3.2% | -2.5% | -1.7% | — |
| May 2, 2023 | AMC | -0.90 | -0.80 | +11.1% | 11.40 | -1.8% | +0.9% | +1.7% | +0.9% | +0.8% | -2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 5 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $28.38 | $34.87 | +22.9% | +33.4% | -4.6% | -2.6% | -1.8% | +9.8% |
| Nov 5 | Jefferies | Upgrade | Hold → Buy | — | $28.38 | $34.87 | +22.9% | +33.4% | -4.6% | -2.6% | -1.8% | +9.8% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.50 | $30.25 | +2.5% | -2.5% | -1.3% | -0.8% | -4.8% | +2.0% |
| Aug 6 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $24.24 | $27.18 | +12.1% | +23.0% | +2.1% | +4.1% | +5.6% | +3.2% |
| May 7 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $18.26 | $22.55 | +23.5% | +1.2% | +2.3% | -0.7% | -0.9% | -1.7% |
| Mar 6 | Citigroup | Maintains | Buy → Buy | — | $20.29 | $20.28 | -0.0% | -2.9% | +4.2% | -4.8% | -0.2% | +4.8% |
| Mar 5 | B. Riley Securities | Maintains | Neutral → Neutral | — | $22.08 | $20.15 | -8.7% | -8.1% | -2.9% | +4.2% | -4.8% | -0.2% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.08 | $20.15 | -8.7% | -8.1% | -2.9% | +4.2% | -4.8% | -0.2% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.81 | $21.57 | -1.1% | +1.5% | +0.1% | -2.0% | +2.0% | +1.5% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.81 | $22.02 | +1.0% | +0.0% | +1.5% | +0.1% | -2.0% | +2.0% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.11 | $17.22 | +0.6% | -2.5% | +7.9% | -3.7% | +16.0% | +8.3% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.16 | $22.37 | -3.4% | -11.2% | -5.0% | -2.7% | -0.5% | +1.2% |
| Dec 10 | B. Riley Securities | Maintains | Neutral → Neutral | — | $23.16 | $22.37 | -3.4% | -11.2% | -5.0% | -2.7% | -0.5% | +1.2% |
| Dec 10 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $23.16 | $22.37 | -3.4% | -11.2% | -5.0% | -2.7% | -0.5% | +1.2% |
| Dec 6 | B. Riley Securities | Maintains | Neutral → Neutral | — | $26.03 | $26.22 | +0.7% | -2.2% | -9.0% | -11.2% | -5.0% | -2.7% |
| Nov 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $27.41 | $27.80 | +1.4% | +0.2% | -12.2% | -5.6% | +5.1% | +1.7% |
| Nov 12 | Citigroup | Maintains | Buy → Buy | — | $24.95 | $25.00 | +0.2% | +9.1% | +0.7% | +0.2% | -12.2% | -5.6% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.43 | $14.43 | +0.0% | -1.9% | +2.5% | -1.2% | -0.5% | -4.5% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.43 | $10.50 | +0.7% | -2.1% | +10.2% | +12.6% | -5.5% | +4.2% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.56 | $9.00 | -5.9% | -11.8% | -6.3% | +20.6% | -13.7% | +2.3% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.53 | $9.50 | -0.3% | -2.8% | -2.5% | +5.8% | -0.5% | +0.6% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.78 | $10.00 | +2.2% | +0.5% | -0.8% | +0.2% | -1.7% | -1.0% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.90 | $11.10 | -6.7% | -16.6% | +2.8% | -3.5% | -0.2% | -3.5% |
| Mar 7 | Citigroup | Maintains | Buy → Buy | — | $15.60 | $15.90 | +1.9% | -1.9% | +2.6% | -3.8% | -1.3% | -2.7% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.80 | $15.40 | +4.1% | +5.4% | -1.9% | +2.6% | -3.8% | -1.3% |
| Mar 6 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $14.80 | $15.40 | +4.1% | +5.4% | -1.9% | +2.6% | -3.8% | -1.3% |
| Mar 6 | B. Riley Securities | Maintains | Neutral → Neutral | — | $14.80 | $15.40 | +4.1% | +5.4% | -1.9% | +2.6% | -3.8% | -1.3% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.20 | $12.10 | +8.0% | +16.1% | +1.5% | +7.6% | +5.6% | +3.3% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.50 | $14.90 | +2.8% | +2.8% | -7.4% | +7.2% | -7.4% | -0.7% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.40 | $11.70 | +2.6% | +16.2% | -3.4% | -2.3% | +4.0% | -1.5% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.30 | $13.50 | +1.5% | -3.0% | -2.3% | -3.2% | -2.5% | -1.7% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.40 | $11.20 | -1.8% | +0.9% | +1.7% | +0.9% | +0.8% | -2.5% |
| Mar 9 | Citigroup | Maintains | Buy → Buy | — | $17.90 | $18.00 | +0.6% | -6.1% | -5.7% | -0.3% | +1.9% | +4.3% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.70 | $18.10 | +23.1% | +21.8% | -6.1% | -5.7% | -0.3% | +1.9% |
| Dec 2 | Citigroup | Upgrade | Neutral → Buy | — | $6.84 | $9.39 | +37.3% | +21.9% | +13.9% | -2.9% | -2.9% | +0.2% |
| Nov 4 | BMO Capital | Maintains | Outperform → Outperform | — | $7.26 | $7.53 | +3.7% | +1.9% | +0.8% | -2.1% | -8.2% | +7.3% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.90 | $17.30 | +8.8% | +1.9% | -6.2% | -2.0% | +15.4% | -4.1% |
| Aug 17 | Piper Sandler | Maintains | Neutral → Neutral | — | $15.60 | $15.40 | -1.3% | +1.9% | +1.9% | -6.2% | -2.0% | +15.4% |
| Jun 9 | B. Riley Securities | Maintains | Neutral → Neutral | — | $7.01 | $7.37 | +5.1% | +2.4% | -6.3% | +3.0% | +5.8% | +11.2% |
| Jun 9 | Citigroup | Downgrade | Buy → Neutral | — | $7.01 | $7.37 | +5.1% | +2.4% | -6.3% | +3.0% | +5.8% | +11.2% |
| Jun 9 | BMO Capital | Maintains | Outperform → Outperform | — | $7.01 | $7.37 | +5.1% | +2.4% | -6.3% | +3.0% | +5.8% | +11.2% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.60 | $8.88 | -49.5% | -60.2% | +2.4% | -6.3% | +3.0% | +5.8% |
| Jun 8 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $17.60 | $8.88 | -49.5% | -60.2% | +2.4% | -6.3% | +3.0% | +5.8% |
| Mar 23 | B. Riley Securities | Maintains | Neutral → Neutral | — | $33.40 | $32.90 | -1.5% | -7.5% | +6.1% | -3.0% | -1.6% | +0.0% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.30 | $53.20 | +17.4% | +5.1% | -2.1% | -1.1% | -11.5% | +7.1% |
| Nov 9 | JP Morgan | Downgrade | Overweight → Neutral | — | $26.20 | $24.90 | -5.0% | -0.4% | +5.0% | +0.7% | -3.3% | +3.0% |
| Aug 6 | Citigroup | Maintains | Buy → Buy | — | $25.20 | $25.00 | -0.8% | -2.4% | +4.9% | +0.8% | -2.3% | -1.6% |
| May 27 | JP Morgan | Maintains | Overweight → Overweight | — | $19.80 | $19.90 | +0.5% | +3.0% | -0.5% | -3.7% | -1.3% | +2.1% |
| Dec 9 | BMO Capital | Maintains | Outperform → Outperform | — | $21.70 | $21.20 | -2.3% | -0.5% | +3.9% | +1.6% | -0.9% | -1.3% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.90 | $23.20 | +1.3% | +2.2% | -3.8% | +0.9% | +3.5% | -4.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | Ali-Jackson Kamil | — | Sell | 2,500 | $29.17 | $73K | 12,625 | +1.46% | -0.17% |
8-K · 8.01
!! High
Arvinas, Inc. -- 8-K 8.01: Material Event / Announcement
Arvinas' previously disclosed May 11, 2026 transaction with subsidiaries Arvinas Operations and Arvinas Estrogen Receptor appears to involve significant corporate restructuring affecting ARVN shareholders.
Jun 16
8-K · 5.02
!!! Very High
Rigel Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
May 20
8-K · 2.02
!! High
Arvinas, Inc. -- 8-K 2.02: Earnings Results
Arvinas reported Q1 2026 financial results and provided a corporate update, though specific revenue and earnings figures require reviewing the detailed filing to assess operational performance and outlook.
May 12
8-K · 1.01
!! High
Arvinas, Inc. -- 8-K 1.01: Collaboration Agreement
May 12
8-K · 1.02
!! High
Rigel Pharmaceuticals Inc. (New) -- 8-K 1.02: Material Agreement Terminated
Rigel Pharmaceuticals terminated its CNS disease program effective June 15, 2026, eliminating a potential revenue stream and narrowing its pipeline focus to other therapeutic areas.
Apr 21
8-K
Rigel Pharmaceuticals Inc. (New) -- 8-K Filing
Rigel Pharmaceuticals reported Q4 2025 revenue from three marketed drugs—TAVALISSE, GAVRETO, and REZLIDHIA—demonstrating progress in its hematologic disorders and cancer portfolio.
Mar 3
8-K · 5.02
!!! Very High
Rigel Pharmaceuticals Inc. (New) -- 8-K 5.02: Executive Change
Rigel Pharmaceuticals appointed Michael P. Miller as a director, potentially strengthening its board governance and oversight capabilities.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 764,193 | $21M | New | Mar 2026 |
| 2 | Acadian Asset Management Llc | 666,426 | $18M | Added | Mar 2026 |
| 3 | Marshall Wace, Llp | 598,378 | $16M | Reduced | Mar 2026 |
| 4 | Morgan Stanley | 332,978 | $14M | Added | Dec 2025 |
| 5 | D.e. Shaw & Co | 445,678 | $12M | Added | Mar 2026 |
| 6 | Jane Street Group, Llc | 275,883 | $12M | Reduced | Dec 2025 |
| 7 | Two Sigma Investments, Lp | 405,807 | $11M | Added | Mar 2026 |
| 8 | Cm Management, Llc | 225,000 | $10M | — | Dec 2025 |
| 9 | Qube Research & Technologies Ltd | 343,897 | $9M | Added | Mar 2026 |
| 10 | Renaissance Technologies Llc | 338,441 | $9M | Reduced | Mar 2026 |
| 11 | Nuveen, Llc | 337,427 | $9M | Added | Mar 2026 |
| 12 | Millennium Management | 264,410 | $7M | Reduced | Mar 2026 |
| 13 | Connor, Clark & Lunn Investment Management Ltd. | 107,969 | $5M | Reduced | Dec 2025 |
| 14 | Arrowstreet Capital, Limited Partnership | 167,342 | $5M | Reduced | Mar 2026 |
| 15 | Vanguard Portfolio Management Llc | 147,535 | $4M | New | Mar 2026 |
| 16 | Bank Of America Corp /de/ | 144,131 | $4M | Added | Mar 2026 |
| 17 | Schroder Investment Management Group | 151,311 | $4M | Added | Mar 2026 |
| 18 | Janus Henderson Group Plc | 135,877 | $4M | New | Mar 2026 |
| 19 | Northern Trust Corp | 134,570 | $4M | Added | Mar 2026 |
| 20 | Citadel Advisors Llc | 131,199 | $4M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$620.0M
Enterprise Value
$487.9M
P/E (TTM)
1.69x
Forward P/E
7.58x
PEG Ratio
0.00x
P/B
1.51x
P/S
2.11x
P/FCF
8.20x
EV/EBITDA
3.82x
Shares Out
18.8M
Financials (TTM)
Revenue
$294.3M
Net Income
$367.0M
EBITDA
$127.9M
Free Cash Flow
$75.7M
Op Cash Flow
$75.7M
EPS Basic
$20.40
EPS Diluted
$19.48
EPS Forward
$4.34
Gross Margin
93.3%
Op Margin
42.6%
Net Margin
124.7%
Balance Sheet
Total Assets
$513.6M
Total Liab.
$122.1M
Total Equity
$391.5M
Cash
$155.0M
LT Debt
$22.9M
Book Value/Sh
$21.76
Debt/Equity
0.14x
Current Ratio
2.42
Quick Ratio
2.30
Returns & Growth
ROE
93.8%
ROA
71.5%
ROIC
28.2%
Rev Growth YoY
+64.1%
EPS Growth YoY
+1960.6%
Price Returns
2W
-4.5%
1M
+5.5%
3M
-12.2%
6M
-39.6%
12M
+58.8%
Technicals
52W High
$50.96
52W Low
$18.42
50d MA
$30.19
200d MA
$34.06
RSI (14)
66.70
ATR (14)
$1.41
Beta
1.27
Avg Volume
405K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$40.00
High
$42.00
Low
$38.00
Median
$40.00
Data updated apr 26, 2026 10:48pm
· Source: financialmodelingprep.com